TR199700652T1 - Insan interlökosit-1 reseptör yardimci proteini. - Google Patents

Insan interlökosit-1 reseptör yardimci proteini.

Info

Publication number
TR199700652T1
TR199700652T1 TR97/00652T TR9700652T TR199700652T1 TR 199700652 T1 TR199700652 T1 TR 199700652T1 TR 97/00652 T TR97/00652 T TR 97/00652T TR 9700652 T TR9700652 T TR 9700652T TR 199700652 T1 TR199700652 T1 TR 199700652T1
Authority
TR
Turkey
Prior art keywords
protein
receptor
kosit
internsan
interl
Prior art date
Application number
TR97/00652T
Other languages
English (en)
Inventor
Chizzonite Richard
Wong Ju Grace
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR199700652T1 publication Critical patent/TR199700652T1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bu bulus, insan IL-1 reseptör yardimci proteinlerini, yalitilmis IL-1 reseptör yardimci proteinlerini ve IL-1 reseptör yardimci proteinlerinin antikorlarini kodlayan polinükleotidlere yöneliktir. Bu protein özellikle IL-1 faaliyetlerinden kaynaklanan iltihaplanmalara karsi etkilidir.
TR97/00652T 1995-01-23 1996-01-17 Insan interlökosit-1 reseptör yardimci proteini. TR199700652T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
TR199700652T1 true TR199700652T1 (tr) 1998-02-21

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/00652T TR199700652T1 (tr) 1995-01-23 1996-01-17 Insan interlökosit-1 reseptör yardimci proteini.

Country Status (19)

Country Link
EP (1) EP0808365A1 (tr)
JP (1) JPH10512453A (tr)
AR (1) AR003919A1 (tr)
AU (1) AU4537096A (tr)
BR (1) BR9606837A (tr)
CA (1) CA2210724A1 (tr)
CO (1) CO4480033A1 (tr)
CZ (1) CZ208197A3 (tr)
EA (1) EA199700265A1 (tr)
FI (1) FI973089A (tr)
HU (1) HUP9702458A2 (tr)
IL (1) IL116796A0 (tr)
MX (1) MX9705501A (tr)
NO (1) NO973404D0 (tr)
PE (1) PE64396A1 (tr)
PL (1) PL321538A1 (tr)
TR (1) TR199700652T1 (tr)
WO (1) WO1996023067A1 (tr)
ZA (1) ZA96333B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
AU755391B2 (en) 1997-12-23 2002-12-12 Immunex Corporation SIGIRR DNA and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
ES2694252T3 (es) 2004-04-02 2018-12-19 Swedish Orphan Biovitrum Ab (Publ) Métodos para reducir la agregación de IL-1ra
PL1751175T3 (pl) * 2004-05-05 2013-03-29 Valorisation Recherche Soc En Commandite Antagoniści receptora IL-1, kompozycje i sposoby leczenia
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
WO2009120903A2 (en) * 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
KR101989134B1 (ko) 2011-01-19 2019-06-13 칸타르기아 아베 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도
CA2837651A1 (en) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018237075A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. ASSESSING THE RISK OF GRAFT COMPLICATION WITH TOTAL ACELLULAR DNA
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CN114835799A (zh) * 2021-05-28 2022-08-02 百奥赛图江苏基因生物技术有限公司 Il1rap基因人源化非人动物的构建方法及应用

Also Published As

Publication number Publication date
CA2210724A1 (en) 1996-08-01
FI973089A0 (fi) 1997-07-22
MX9705501A (es) 1997-10-31
CZ208197A3 (en) 1997-11-12
PE64396A1 (es) 1997-01-28
ZA96333B (en) 1996-07-23
PL321538A1 (en) 1997-12-08
EA199700265A1 (ru) 1998-04-30
WO1996023067A1 (en) 1996-08-01
HUP9702458A2 (hu) 1998-04-28
AU4537096A (en) 1996-08-14
JPH10512453A (ja) 1998-12-02
IL116796A0 (en) 1996-05-14
EP0808365A1 (en) 1997-11-26
NO973404L (no) 1997-07-23
BR9606837A (pt) 1998-05-26
AR003919A1 (es) 1998-09-30
CO4480033A1 (es) 1997-07-09
NO973404D0 (no) 1997-07-23
FI973089A (fi) 1997-07-22

Similar Documents

Publication Publication Date Title
TR199700652T1 (tr) Insan interlökosit-1 reseptör yardimci proteini.
CY1117551T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
TR199802423T2 (tr) Konsantre antikor terkibi.
DE68916722D1 (de) Urethan geschützte aminosäuren-n-carboxyanhydride.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
MX9301655A (es) Purificacion de proteina.
TR199501421A2 (tr) Amino gruplarini secici bir sekilde acillenmesi.
ATE399177T1 (de) Derivate therapeutischer peptide
BR9808934A (pt) Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
DK0746398T3 (da) Antistofrensning
DK0712931T4 (da) Interferon-gamma-produktionsinducerende polypeptid, monoklonalt antistof og middel mod sygdomme, der responderer på interferon-gamma
FI963004A (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE69637845D1 (de) Synthetische peptide mit il-6 aktivitäthemmung
ATE267213T1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
FR2759701B1 (fr) Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
MX9302549A (es) Proteina receptora especifica para la region csvt cg de la trombospondina y metodo para su purificacion y caracterizacion.
DZ2803A1 (fr) Polypeptide de la protéine c humaine.
TR199501282A2 (tr) Glükagon-gibi ensülinotropik peptid analoglari, bilesimleri ve kullanim yöntemleri.
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52
BR7500814U (pt) Válvula de escape rápido alternativa
ES1025752Y (es) Collar de denticion sintetico de uso terapeutico.